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Abstract
Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive
disorder caused by mutations in TYMP gene, encoding nuclear thymidine phosphorylase (TP). MNGIE mainly
presents with gastrointestinal symptoms and is mostly misdiagnosed in many patients as malabsorption syndrome,
inflammatory bowel disease, anorexia nervosa, and intestinal pseudo-obstruction. Up to date, more than 80
pathogenic and likely pathogenic mutations associated with the disease have been reported in patients from a
wide range of ethnicities. The objective of this study was to investigate the underlying genetic abnormalities in a
25-year-old woman affected with MNGIE.
Case presentation: The patient was a 25-year-old female referred to our center with the chief complaint of severe
abdominal pain and diarrhea for 2 years that had worsened from 2 months prior to admission. The clinical and
para-clinical findings were in favor of mitochondrial neurogastrointestinal encephalomyopathy syndrome.
Subsequent genetic studies revealed a novel, private, homozygous nonsense mutation in TYMP gene (c. 1013 C > A,
p.S338X). Sanger sequencing confirmed the new mutation in the proband. Multiple sequence alignment showed
high conservation of amino acids of this protein across different species.
Conclusion: The detected new nonsense mutation in the TYMP gene would be very important for genetic
counseling and subsequent early diagnosis and initiation of proper therapy. This novel pathogenic variant would
help us establish future genotype-phenotype correlations and identify different pathways related to this disorder.
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thy (MNGIE – OMIM# 603041) is a rare multisystem
autosomal recessive disorder caused by homozygous
or compound heterozygous mutations in the nuclear-
encoded thymidine phosphorylase gene (TYMP; 131,
222) on chromosome 22q13, the first gene whose role
was defined at molecular level in the defects of inter-
genomic communication [1]. Impairment in this en-
zyme with resultant decreased enzyme activity leads
to accumulation of the enzyme’s substrates, thymidine
and deoxyuridine, which in turn leads to an imbal-
ance in the intra-mitochondrial nucleotide pool and
multiple deletions, point-specific mutations and deple-
tions in mitochondrial DNA (mtDNA) [2, 3]. Earlier
studies have suggested that the accumulation of these
nucleosides is the main culprit for the development
of the molecular and phenotypic aberrations reported
in this disorder [4–6].
First described in 1976, MNGIE usually presents be-
fore the age of 30 years with a mean age of onset of 18.5
years. Nevertheless, there have been a few patients where
onset was as early as 5 months of age and as late as the
fifth decade [7–9]. The disease has a progressive clinical
course leading to death at the mean age of 37 [9–12].
The clinical manifestations of MNGIE are severe gastro-
intestinal dysmotility, cachexia, extraocular muscle
weakness with resultant ptosis and ophthalmoplegia,
sensorimotor neuropathy, and leukoencephalopathy [13].
More than 120 patients with diagnostic features consist-
ent with MNGIE have so far been reported in the litera-
ture, with more than 80 pathogenic and likely
pathogenic mutations (https://www.ensembl.org) associ-
ated with the disease identified in patients from a wide
range of ethnicities [14, 15].
Herein, we report on a patient with MNGIE with a
novel homozygous mutation in TYMP gene, along with
the clinical, laboratory and imaging findings.
Case presentation
Clinical presentation
A 25-year-old female was referred to our center with the
chief complaint of severe abdominal pain and diarrhea
for 2 years that had worsened from 2 months prior to
admission. She had significant weight loss during this
period; weighing 36.5 kg with a height of 160 cm, her
body mass index (BMI) was 14.3 kg/m2 at the time of
admission. Her past medical and surgical history was
only significant for one undocumented episode of seiz-
ure at the age of three and appendectomy 3 years before.
On interview, she denied fear of weight gain, laxative
abuse, and self-induced vomiting. Her parents were con-
sanguineous. There was no history of sibling loss or any
similar symptoms in other family members.
Clinical examination revealed a cachectic lady with ex-
ternal ophthalmoplegia, ptosis, right lower quadrant scar
of the McBurney (oblique) incision for appendectomy,
decreased muscle power in the upper (4/5 MRC muscle
scale) and lower (3/5 MRC muscle scale) extremities,
and absent deep tendon reflexes. Abdominopelvic son-
ography revealed mild free fluid in the abdominal cavity
and increased thickness in the bowel wall (4.8 mm) and
a 16 × 11-mm cortical cyst in the upper pole of the left
kidney with thin septation. A diagnostic esophago-
gastro-duodenoscopy showed diffuse severe erythema
and congestion in the body, fundus, and antrum of the
stomach with moderate chronic gastritis in pathologic
examination and deformity of the duodenal bulb with
decreased folds in D2 part of the duodenum. On colon-
oscopy, the ileocecal valve was stenotic; biopsy revealed
submucosal fibrosis with lymphoid proliferation and
focal ulceration. Echocardiography was normal except
for mild pericardial effusion.
Her complete blood count indicated the presence of
microcytic hypochromic anemia. Biochemistry revealed
low total protein level (4.1 g/dl; reference range: 6.6–8.8 g/
dl) and albumin (2.2 g/dl; reference range: 3.5–5.2 g/dl).
Serum lactate level (35.3 mg/dl; reference range: 4.5–19.8
mg/dl) was elevated. Fecal occult blood test was positive
with moderately elevated fecal calprotectin level (58.5 μg/
g; reference range: < 15 μg/g) suggestive for the inflamma-
tory process. Cerebrospinal fluid analysis revealed marked
elevation of protein level (122mg/dl; reference range: 15–
45mg/dl). Serology tests for HIV, HBV, and HCV were
negative. Serum anti-tissue trans-glutaminase antibodies,
anti-phospholipid antibodies, anti-cardiolipin antibodies,
lupus anti-coagulants, β2 microglobulin, anti-nuclear anti-
body (ANA), anti-double stranded DNA (anti-dsDNA), C-
ANCA, and P-ANCA were also within the normal limits.
Serum levels of complement factors were also found to be
altered: C3 level (65 mg/dl; reference range: 90–180mg/dl)
was decreased; C4 level (11.4 mg/dl; reference range: 10–
40mg/dl) was within the lower limit of the normal range.
Blood TP activity was not measured for lack of laboratory
resources.
The electrodiagnostic evaluation showed a neurogenic
pattern on needle electromyography (EMG), conduction
block in sensory nerves, and decreased compound muscle
action potential (CMAP) in motor nerves with decreased
conduction velocity and prolonged F-wave latency. Brain
MRI with contrast showed leukoencephalopathy with dif-
fusely increased T2 signal intensity in both cerebral hemi-
spheres white matter. Hypersignal intensity in splenium of
corpus callosum was also observed (Fig. 1).
Molecular analysis
After obtaining informed consent, a blood sample was
obtained from the patient. The whole blood sample was
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collected in EDTA tube. Genomic DNA was then ex-
tracted from peripheral leukocytes using the QIAamp
DNA Blood Mini Kit (Qiagen, Germany).
Whole Exome Sequencing (WES) was performed on
Illumina NextSeq500 instrument to a sequence close to
100 million reads. WES result was then analyzed using
different bioinformatics tools and databases such as
BWA aligner, GATK and ANNOVAR [16–18]. WES un-
covered a novel, private, homozygous stopgain mutation
in TYMP gene (NM_001113756: exon7: c. 1013C > A:
p.S338X, Chr: 50526392).
Subsequently in order to confirm this novel mutation
using Sanger sequencing, the region of interest was amp-
lified using PCR on the DNA of the proband using fol-
lowing primers: F–TYMP-E7: 5′-ACTTAAGGGACCTG
GTCACCAC-3′ and R–TYMP-E7: 5′-AGCCTCTGAC
CCACGTCGA-3′ (PCR product: 594 bp). Then, the
amplicon was sequenced with both forward and reverse
primers using ABI BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems®, USA). Sanger sequencing re-
sult was analyzed by NCBI BLAST (https://blast.ncbi.
nlm.nih.gov) and CodonCode Aligner (http://www.
codoncode.com/aligner/). Sanger sequencing confirmed
this mutation as homozygous in the proband (Fig. 2).
This mutation has not been reported yet in main vari-
ant databases and our public database (Bayangene). The
mutation occurred in domains described as Glycos_
transf_3 in Pfam database or Nucleoside phosphorylase/
phosphoribosyltransferase catalytic domain in Gene3D
database which affects this domain and other domains
such as PYNP_C, Pyrimidine nucleoside phosphorylase
C-terminal domain, TIGR02644, THYMIDINE PHOS-
PHORYLASE and TP_PyNP which are described by a
different database.
To reveal the conservation of amino acid sequence of
TYMP protein across various species, multiple sequence
alignment analysis by BLAST available on ExPASy
(https://web.expasy.org/cgi-bin/blast/blast.pl) was also
Fig. 1 Brain MRI revealing diffuse white matter signal changes
Fig. 2 Sanger sequencing electropherogram of the novel identified variant in this study. The arrow shows the position of homozygous mutation
in TYMP (c. 1013 C > A, p.S338X)
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performed. Multiple sequence alignment showed high
conservation of amino acids of this protein across differ-
ent species, mainly in the mutated region and after this
position. (Fig. 3).
Discussion and conclusion
A group of mitochondrial disorders are characterized by
mutations in the nuclear genome affecting expression
and replication of the genes on the mitochondrial gen-
etic material. Progressive external ophthalmoplegia
(PEO) was the first disease identified in this group
caused by defects in the intergenomic communication
[19]. MNGIE, a rare progressive multisystem autosomal
recessive disorder caused by a mutation in TYMP gene
is also a member of this group of disorders.
TYMP gene which encodes the cytosolic enzyme
named thymidine phosphorylase, TP, is located at
chromosome 22q13.33. This protein catalyzes phospho-
rolysis of thymidine and deoxyuridine to 2-deoxyribose
1-phosphate and their corresponding bases (Fig. 4). TP
plays both a direct and an indirect role in the metabolic
pathways of various cells including those in the brain,
muscle, WBCs, and bone marrow [20]. Absence of TP in
cells which normally have a high expression of the en-
zyme (e.g., white blood cells) leads to systemic accumu-
lation of dThd and dUrd which has a toxic effect on
other tissues [21]. MNGIE usually presents with
symptoms of gastrointestinal dysfunction, such as
gastrointestinal motility disorders, gastro-esophageal re-
flux, dysphagia, abdominal pain and distention, and diar-
rhea leading to severe weight loss and cachexia [22]. At
this stage of the disease, most of the patients are mis-
diagnosed as malabsorption syndrome, inflammatory
bowel disease (IBD), anorexia nervosa, or intestinal
pseudo-obstruction, often leading to unnecessary med-
ical interventions and delay in diagnosis of up to 10 years
[11, 23–25]. Gastrointestinal signs and symptoms have
also been observed in other genetic mitochondrial disor-
ders as well [26]. Ptosis, ophthalmoparesis, hearing loss,
and sensory-motor neuropathy constitute the most com-
mon neurologic features of patients with MNGIE [13].
Due to the high metabolic activity of extraocular mus-
cles, deterioration in their function resulting in ophthal-
moplegia or ophthalmoparesis occurs early in the course
of the disease that parallels the disease progression [27].
Neuroimaging studies such as brain MRI and magnetic
resonance spectroscopy (MRS) might yield a clue about
the diagnosis of MNGIE, with the absence of leukoence-
phalopathy ruling out MNGIE in most cases. Unlike the
patient reported here, who had involvement of splenium
of the corpus callosum, it is relatively spared in most in-
dividuals [13, 15, 28]. Our patient was found to have leu-
koencephalopathy, with diffuse T2 hyperintensity in both
cerebral hemispheres white matter on brain MRI,
Fig. 3 Multiple sequence alignment of the whole amino acid sequence of TYMP with other TYMP orthologs across different species
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though, she had normal cognitive function. This, in turn,
is likely to be due to the impaired blood-brain barrier
function in these patients leading to edema in lieu of de-
myelination [29].
Other disorders with phenotypes similar to MNGIE,
caused by mutations in RRM2B and POLG genes have
been reported [30, 31]. Therefore, it is prudent to test
the individuals suspected of having MNGIE for these
genes as well. In our patient whole exome sequencing
was done and no mutations in these genes were
detected.
To the best of our knowledge, around 80 patho-
genic mutations in the TYMP gene have so far been
reported. Attempts to draw a genotype-phenotype
correlation in this disorder have mostly been discour-
aging, except for c. 622G > A variant (p.Val208Met),
producing less severe TP dysfunction, leading to a
late-onset disease [8, 32, 33].
Current treatment modalities for MNGIE mainly focus
on restoration of the activity of TP and lowering the cir-
culatory levels of the nucleoside substrates.
Hematopoietic stem cell transplantation (HSCT) has so
far been used to restore TP enzyme activity in patients
with MNGIE. A retrospective analysis of 24 patients
who underwent HSCT for the treatment of MNGIE re-
vealed a survival rate of 37.5% after a median follow-up
of almost 4 years. Of the fifteen patients who had died,
nine had died from transplant-related mortality, and six
from their disease [34]. It was found that younger pa-
tients without gastrointestinal dysmotility and liver dis-
ease receiving HSCT from an HLA-matched donor
would benefit mostly from this type of treatment,
highlighting the importance of diagnosis in the momen-
tous days early in the course of the illness, when HSCT
would change the course of the disease [34].
Hemodialysis and peritoneal dialysis have also been pro-
posed as treatment modalities in these patients intending
to remove the nucleosides from the peripheral circula-
tion. In a 20-year-old patient with MNGIE, peritoneal
dialysis was shown to remove approximately 100 μ moles
per day of thymidine and 2′-deoxyuridine from the peri-
toneal cavity. Although there were improvements in the
symptoms, nucleosides serum levels remained un-
changed [35]. A prospective study evaluating a 29-year-
old patient with MNGIE who underwent extensive
hemodialysis for 1 year also revealed that it has only a
transient effect on the serum and urine levels of nucleo-
sides with no long-term effects; there were no changes
in the level of the toxic metabolites in the CSF in both
short-term (within 24 h) and long-term (at months 6
and 12) [36]. Our patient in this report underwent
hemodialysis with only mild improvements in the
gastrointestinal symptoms. These findings cast doubt on
the efficacy of dialysis in the treatment of MNGIE. Other
therapeutic modalities including platelet infusion, which
was also performed in our patient, and orthotopic liver
transplantation have also been reported for the treat-
ment of this disease in the literature [37, 38]. Erythrocyte
encapsulated thymidine phosphorylase (EE-TP) enzyme
replacement therapy which has clinical trial approval is
another promising treatment option [39].
The mutation found initially by WES and subse-
quently confirmed using Sanger sequencing is pre-
dicted to disrupt the proper function of TYMP
protein since different reports have identified frame-
shift mutations before and after this region resulting
in the impaired TYMP [7, 40, 41].
Our patient had many of the clinical, laboratory, and
imaging features seen in MNGIE. The detected novel
nonsense mutation in the TYMP gene would be of im-
portance for genetic counseling and subsequent early
diagnosis and initiation of proper therapy. On account
of the wide clinical spectrum of signs and symptoms
presented by patients with MNGIE, molecular diagnostic
methods would be of paramount importance.
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